MedPath

Comparison of postoperative pain for 0.5% hyperbaric bupivacaine given as spinal block with intravenous or spinal dexmedetomidine in abdominal hysterectomy.

Not yet recruiting
Conditions
Medical and Surgical,
Registration Number
CTRI/2022/05/042588
Lead Sponsor
JLN medical college and hospital
Brief Summary

The aim of our study is compare of intravenous and intrathecal dexmedetomidine as adjuvants to 0.5% hyperbaric bupivacaine in abdominal hysterectomy with respect to

PRIMARY OBJECTIVE : Duration of post operative analgesia

SECONDARY OBJECTIVES : Onset and recovery of sensory block, onset or recovery of motor block, peri operative sedation score,haemodyanamic changes, adverse effect if any.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
100
Inclusion Criteria
  • 1.body weight 40 to 80 kg.
  • 2.Patient belonging to ASA class I and II.
  • 3.Patient undergoing abdominal surgery.
Exclusion Criteria
  • 1.Patient refusal or uncooperative patient.
  • 2.Any known hypersensitivity or contraindication to bupivacaine, dexmedetomidine.
  • 3.Local pathology at the site of injection or disability limiting the performance of spinal block.
  • History of convulsion, bleeding disorder, severe neurological deficit, thyroid disorder.
  • Patient with history of respiratory,cardiac,hepatic or renal disease.
  • Patient having a history of significant neurological,psychiatric or neuromuscular disorders.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Duration of analgesia.1 year
Secondary Outcome Measures
NameTimeMethod
Onset and recovery(time to 2 segment regression) of sensory block.Onset and recovery of motor block,

Trial Locations

Locations (1)

J.L.N medical college and hospital

🇮🇳

Ajmer, RAJASTHAN, India

J.L.N medical college and hospital
🇮🇳Ajmer, RAJASTHAN, India
Dr Durga lal yadav
Principal investigator
9252255176
drdly10@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.